Appropriate durations of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumor (GIST) the better choice, for the year 2010
We report a case of a patient with histopathologically diagnosed GIST who had undergone complete tumor resection for primary localized lesion. The patient has received adjuvant imatinib treatment for at least two years. Studies have shown an improvement in RFS with 1 year of adjuvant imatinib, there...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd
2015-10-01
|
| Series: | Clinical Management Issues |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1125 |